We are frequently consulted by patients with treatment resistant depression (TRD).Reference Fogelson and Leuchter1 Many of these patients have never met criteria for a manic episode so they are not diagnosed with bipolar disorder (BPD). Consequently, they have undergone trials of antidepressants with or without augmentation therapies without success.Reference Perlis, Uher [...]
No pharmacological agents are approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis (DRP). Pimavanserin, an atypical antipsychotic that acts as a selective serotonin inverse agonist/antagonist at 5-HT2A receptors (and to a lesser extent, at 5-HT2c receptors), is the only FDA-approved treatment for hallucinations and delusions associated with [...]
The federal government on Thursday proposed new guidelines for prescribing opioid painkillers that remove its previous recommended ceilings on doses for chronic pain patients and instead encourage doctors to use their best judgment. The new guidelines were reported in today's New York Times But the overall thrust of the recommendations [...]
Valid assessment of drug efficacy and safety requires an evidence base free of reporting bias. Using trial reports in Food and Drug Administration (FDA) drug approval packages as a gold standard, researchers, Turner, Cipriani, Furukawa, et al. previously found that the published literature inflated the apparent efficacy of antidepressant drugs. [...]
A group of researchers aimed to determine the risks of premature mortality and suicide in people with common noncommunicable diseases, with and without psychiatric disorder comorbidity. In this longitudinal study of over 1 million patients with chronic health diseases, researchers observed increased risks of all-cause and suicide mortality in individuals [...]
ORIGINAL RESEARCH Doxepin for Insomnia: Executive Function before and after Treatment By Zhenghe YU, Li HAN, Pan YAN, Wenjuan LIU, Lishan REN, You XU, Lili YANG, Lisha MA, Youdan WEI, Yi LIU, Shengdong WANG DRUG DISPOSITION AND PHARMACOKINETICS Protein Biomarkers in Monocytes and CD4+ Lymphocytes for Predicting Lithium Treatment Response of [...]
Orally dissolving medications containing buprenorphine are linked to severe dental problems, including total tooth loss, the US Food and Drug Administration (FDA) warns in a safety communication. The oral side effects of these medications, which are used to treat opioid use disorder (OUD) and pain, include cavities/tooth decay, including rampant caries; dental abscesses/infection; tooth [...]
Aaron "Tim" Beck, MD, known as the father of cognitive behavioral therapy (CBT), died on Monday in Philadelphia. He was 100. Beck's pioneering career in psychoanalysis spanned more than seven decades, yielding more than 600 published articles and nearly two dozen books. His development of CBT redefined the practice of [...]
The antidepressant fluvoxamine (Luvox) may prevent hospitalization and death in outpatients with COVID-19, new research suggests. Results from the placebo-controlled, multisite, phase 3 TOGETHER trial showed that in COVID-19 outpatients at high risk for complications, hospitalizations were cut by 66% and deaths were reduced by 91% in those who tolerated fluvoxamine. "Our [...]
The US Food and Drug Administration (FDA) has approved a high-dose naloxone injection product for the emergency treatment of opioid overdose. ZIMHI from Adamis Pharmaceuticals is administered using a single-dose, prefilled syringe that delivers 5 mg of naloxone hydrochloride solution through intramuscular or subcutaneous injection. Naloxone is an opioid antagonist [...]